Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from SAI Life Sciences Ltd. ( (IN:SAILIFE) ).
Sai Life Sciences Limited reported a significant 77% year-on-year revenue growth for the first quarter of Fiscal Year 2026, driven by strong performance in its CDMO segment. The company achieved a revenue of ₹496 crore, an EBITDA of ₹125 crore, and a net profit of ₹60 crore. The company expanded its manufacturing capacity and research capabilities, inaugurating new facilities and investing in infrastructure to support complex drug development. These developments reflect the company’s strategic focus on enhancing its service offerings and strengthening its position in the global pharmaceutical market.
More about SAI Life Sciences Ltd.
Sai Life Sciences Limited is a Contract Research, Development, and Manufacturing Organization (CRDMO) focused on innovation. The company operates in the pharmaceutical industry, providing services in drug discovery, development, and commercial manufacturing, with a strong emphasis on complex peptides and emerging modalities.
Average Trading Volume: 366,016
Technical Sentiment Signal: Strong Buy
Current Market Cap: 165.6B INR
Learn more about SAILIFE stock on TipRanks’ Stock Analysis page.